Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Average NHI-Market Price Gap at “Around 8%”, MHLW Reveals to LDP Bigwigs; Total Savings Undisclosed
December 3, 2019
- Ryukaikon’s Dec. 9 Meeting Likely to Be Put Off in Wake of Bid-Rigging Scandal
December 3, 2019
- Causal Link between Eisai’s Epilepsy Drug and Trial Death Can’t Be Ruled Out: MHLW
December 2, 2019
- MHLW Panel OKs Eisai’s Insomnia Med, Fycompa’s Monotherapy and More
December 2, 2019
- Use of Antibiotics in Japan Down 10.6% in 2018 vs. 2013: MHLW
December 2, 2019
- Komeito Calls for System to Reward Useful New Indications
November 29, 2019
- Japan Pharma Industry Chief Raises Alarm over Comparator PMP Deduction Proposal: LDP Study Group
November 29, 2019
- Govt Panel to Draw Up New AMR Action Plan for 2021 and Beyond
November 29, 2019
- Amended PMD Law Set for 3-Step Enforcement, 1st Execution Eyed Next Autumn
November 28, 2019
- LDP to Forge Lawmakers’ League Aimed to Reinstate HPV Vaccine Recommendation
November 27, 2019
- “All-Generation” Panel Cites Coverage of OTC-Like Drugs as Policy Issue
November 27, 2019
- Japan Enacts Amended Pharmaceuticals and Medical Devices Law
November 27, 2019
- Japan’s First Biosimilars of Avastin, Nesp, Forteo Receive Listing
November 27, 2019
- MOF Panel Leery of Pricey Drugs for Huge Patient Population: FY2020 Budget Recommendation
November 26, 2019
- MHLW Panel OKs Bayer’s Xtandi Rival, AbbVie’s JAK Inhibitor; 2 More Keytruda Usages Now in Line for Approval
November 26, 2019
- MHLW Panel Members Call for Need to “at Least Discuss” Whether to Resume Actively Recommending HPV Vaccines
November 26, 2019
- Plaintiffs of HPV Vaccine Suits Prod JMA to Hear Stories of Victims
November 26, 2019
- MHLW Floats 2 Rules to Address Unreasonable Price Rises for Listed Generics
November 26, 2019
- Xolair’s Pollen Allergy Nod Delayed as Novartis Says It Needs More Time to Prepare for Launch
November 25, 2019
- Chuikyo Members Remain Divided over Timing of Comparator PMP Removal
November 25, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…